Effective management requires individualized dose escalation, patient education, and nonpharmacologic strategies
The American Diabetes Association (ADA) recommends [archived link] GLP-1 RAs as first-choice Type 2 diabetes medication options in many cases
Pfizer provides update on oral GLP-1 receptor agonist danuglipron
For instance, a clinical trial of 11,000 people found that using GLP-1 RAs reduced kidney disease progression by 18%, kidney failure by 16% and risk of cardiac events by 13%
While this particular study has yet to be published in a peer-reviewed journal, another study published in February in the Journal of Clinical Endocrinology & Metabolism connected the medications with a higher risk of getting osteoporosis-related fractures for older adults with type 2 diabetes
Real microneedle patches are an advanced, legitimate medical technology still in clinical trials designed to painlessly deliver actual medication